title: A program to convert patients from trade-name to generic clozapine.
abstract: In spring 2000, the Missouri Department of Mental Health mandated that its psychiatric inpatient facilities convert patients from trade-name to generic clozapine. The pharmacy department at our facility was encouraged to develop a conversion program to oversee and assess the efficacy and tolerability of the change. A protocol to monitor the conversion of patients to generic clozapine hospitalwide was developed. The primary objective was to determine whether therapeutic response and level of tolerability were the same with generic versus trade-name clozapine. The secondary objective was to determine whether changes in monitoring white blood cell and absolute neutrophil counts were necessary after conversion. Our results showed that most patients did not experience changes greater than a mean of 5 points in their scores on the Brief Psychiatric Rating Scale (BPRS). However, a statistically significant difference was seen in 22 patients who had a mean reduction or an increase of less than 5 points (p=0.0139) in BPRS scores compared with two patients who had a mean increase greater than 5 points. Assessment of percentage change in BPRS scores indicated that 14 (58%) converted patients had a 1-50% decrease in mean BPRS scores, and 10 (42%) had a 1-40% increase. However, of those with a mean BPRS increase, five (50%) had an increase of 10% or less. Our clozapine conversion program resulted in the successful conversion of all 24 patients.
authors.affiliation: University of Missouri-Kansas City School of Pharmacy, Kansas City, Missouri, USA.
authors.forename: Steven C
authors.initials: SC
authors.lastname: Stoner
authors.forename: Jessica W
authors.initials: JW
authors.lastname: Lea
authors.forename: Beth
authors.initials: B
authors.lastname: Dubisar
authors.forename: Patricia A
authors.initials: PA
authors.lastname: Marken
authors.forename: Leonard V
authors.initials: LV
authors.lastname: Ramlatchman
authors.forename: James
authors.initials: J
authors.lastname: Reynolds
mesh_terms: D000328:Adult; D014150:Antipsychotic Agents / Q000009:adverse effects / Q000097:blood / Q000627:therapeutic use*; D010054:Brief Psychiatric Rating Scale; D003024:Clozapine / Q000009:adverse effects / Q000097:blood / Q000627:therapeutic use*; D016568:Drugs, Generic; D006801:Humans; D012559:Schizophrenia / Q000188:drug therapy*; D013810:Therapeutic Equivalency; D016896:Treatment Outcome
chemical_list: D014150:Antipsychotic Agents; D016568:Drugs, Generic; D003024:Clozapine